

Pandemic H1N1 (pH1N1) Influenza Vaccine Quick Reference Guide

The adjuvanted pandemic H1N1 influenza vaccine is a two component vaccine:

Antigen	Split virus, inactivated, A/California/7/2009(H1N1)-like strain, isolated form virus propagated in eggs	Colorless to slightly opalescent, suspension that may sediment slightly
Adjuvant	DL α -tocopherol, squalene, polysorbate 80	Sterile, homogenized, whitish emulsion

When reconstituted:

Trade Name	Contents	Other comments	
AREPANRIX™ H1N1	Thimerosal, a mercury derivatives added as a preservative Each dose contains 2.5 mcg. of mercury, squalene, vitamin E, polysorbate 80. Trace amounts of egg proteins, formaldehyde, sodium deoxycholate and sucrose. Other contents: sodium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride, water for injections.	Rubber stopper on both vials is butyl rubber without latex. No antibiotics	When reconstituted contains enough vaccine for 10 doses (0.5 ml/dose)

Source: Product information leaflet Arepanrix™H1N1 GlaxoSmithKline Oct 21, 2009

Unadjuvanted pandemic H1N1(pH1N1) vaccine:

Trade Name	Description	Contents	Other comments
Panvax®H1N1 To be used for pregnant females only	Purified, monovalent split virus vaccine. A/California/7/2009 (H1N1) prepared from influenza virus propagated in the fluid of embryonated chicken eggs	Each dose contains: Sodium taurodeoxycholate, ovalbumin, sucrose, neomycin, polymyxin B sulfate, beta-propiolactone. Thimerosal 50 mcg used as a preservative Other contents: sodium chloride, sodium phosphate-dibasic anhydrous, sodium phosphate-monobasic, potassium chloride, potassium phosphate-monobasic, calcium chloride	Multidose vial Stopper is latex free Must be used within 28 days once stopper pierced. Contains antibiotics – neomycin, polymyxin B sulfate. Shake well before using. Clear to slightly opaque liquid with some sediment that resuspends upon shaking.
Influenza A (H1N1) 2009 Pandemic Monovalent Vaccine (without adjuvant)	Monovalent, inactivated split virus. A/California/7/2009(H1N1-like strain) prepared from the virus grown in the allantoic cavity of embryonated hens' eggs.	The vaccine contains: trace residual amounts of egg proteins, formaldehyde, sodium deoxycholate and sucrose. Thimerosal 50 mcg. is used as a preservative. Other contents: sodium chloride, potassium chloride, sodium phosphate dibasic heptahydrate, potassium phosphate monobasic and water	Multi-dose vial Antibiotics are not used. Packaging does not contain latex. Once entered, must be used within 28 days. Translucent to whitish opalescent suspension that may sediment slightly

Source: Product information leaflet, Panvax ®H1N1, CSL Biotherapies, Australia, September 15, 2009

Source: Product Information leaflet, Influenza A(H1N1) 2009 Pandemic Monovalent Vaccine(without adjuvant), GSK, Nov 1, 2009

November 16, 2009

Current pH1N1 Vaccines – Summary of Recommended Use

Category of person	Adjuvanted - AREPANRIX™ H1N1	Unadjuvanted Panvax® H1N1	Unadjuvanted GSK – pH1N1 without adjuvant	Dosage	Route	Needle length/Gauge	Comments
Adults and children over 10 years of age	√		*	0.5ml	IM Deltoid	22-25 G 1”-1 ½”	*Unadjuvanted vaccine may be used in individuals age 10 years to 64 years with healthy immune systems, either on request or if adjuvanted vaccine not available.
Pregnant women	** (> 20 weeks or with high risk conditions)	√ preferred	√ preferred	0.5 ml	IM Deltoid	22-25 G 1”-1 ½”	**Adjuvanted vaccine may be recommended to pregnant women > 20 weeks if there is H1N1 disease in the community and unadjuvanted vaccine is not available. ** Women < 20 weeks pregnant with underlying high risk conditions should consider adjuvanted vaccine, but should consult their primary care provider. √ Women < 20 weeks pregnant with no underlying health conditions should receive unadjuvanted vaccine only.
Children 6 mos- 9 years	√			Adjuvanted - AREPANRIX™ H1N1: 6 months through 35 months of age: Two 0.25 mL doses, approximately 21 days apart; Healthy 36 months through 9 years of age: One 0.25 mL dose; 36 months through 9 years of age with chronic disease: Two 0.25 mL doses approximately 21 days apart.	IM Deltoid >12 mos old Vastus lateralis - 6 mos- 12 mos old	22- 25 g 1” 22- 25 g 1”	

Source: Product information leaflet Arepanrix™H1N1 GlaxoSmithKline Oct 21, 2009,

Product information leaflet, Panvax ®H1N1, CSL Biotherapies, Australia, September 15, 2009

PHAC 2009

Source: Product Information leaflet, Influenza A(H1N1) 2009 Pandemic Monovalent Vaccine(without adjuvant), GSK, Nov 1, 2009

November 16, 2009